Condensed Consolidated Financial Statements Detail (Tables)
|
6 Months Ended |
Jun. 30, 2017 |
|---|
| Condensed Consolidated Financial Statements Detail [Abstract] |
|
| Trade and Other Receivables |
Trade and other receivables consisted of the following (in thousands):
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
|
2017
|
|
|
2016
|
|
|
Trade receivables, net
|
|
$
|
10,546
|
|
|
$
|
474
|
|
|
Other receivables
|
|
|
85
|
|
|
|
92
|
|
|
Trade and other receivables, net
|
|
$
|
10,631
|
|
|
$
|
566
|
|
|
| Property and Equipment, Net |
Property and equipment, net consisted of the following (in thousands):
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
|
2017
|
|
|
2016
|
|
|
Equipment and furniture
|
|
$
|
1,921
|
|
|
$
|
14,023
|
|
|
Leasehold improvements
|
|
|
334
|
|
|
|
554
|
|
|
|
|
|
2,255
|
|
|
|
14,577
|
|
|
Less: Accumulated depreciation and amortization
|
|
|
(2,021
|
)
|
|
|
(13,541
|
)
|
|
Property and equipment, net
|
|
$
|
234
|
|
|
$
|
1,036
|
|
|
| Accrued and Other Liabilities |
Accrued and other liabilities consisted of the following (in thousands):
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
|
2017
|
|
|
2016
|
|
|
Accrued payroll and other benefits
|
|
$
|
138
|
|
|
$
|
1,582
|
|
|
Accrued clinical trial costs
|
|
|
389
|
|
|
|
743
|
|
|
Accrued incentive compensation
|
|
|
134
|
|
|
|
—
|
|
|
Accrued legal and accounting fees
|
|
|
641
|
|
|
|
385
|
|
|
Other
|
|
|
760
|
|
|
|
1,505
|
|
|
Total
|
|
$
|
2,062
|
|
|
$
|
4,215
|
|
|
| Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Income (Loss) Per Share Available to Common Stockholders |
The following is a reconciliation of the numerator (net income or loss) and the denominator (number of shares) used in the calculation of basic and diluted net income (loss) per share available to common stockholders (in thousands):
|
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
Numerator
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
285
|
|
|
$
|
(15,160
|
)
|
|
$
|
(10,429
|
)
|
|
$
|
(23,525
|
)
|
|
Less: Deemed dividend on convertible preferred stock
|
|
|
—
|
|
|
|
—
|
|
|
|
(5,603
|
)
|
|
|
—
|
|
|
Less: Allocation of undistributed earnings to participating securities
|
|
|
(113
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Net income (loss) available to common stockholders, basic and diluted
|
|
$
|
172
|
|
|
$
|
(15,160
|
)
|
|
$
|
(16,032
|
)
|
|
$
|
(23,525
|
)
|
|
Denominator
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding used for basic net income (loss) per share available to common stockholders
|
|
|
7,588
|
|
|
|
6,022
|
|
|
|
7,240
|
|
|
|
6,000
|
|
|
Effect of dilutive stock options
|
|
|
55
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Weighted average shares outstanding used for diluted net income (loss) per share available to common stockholders
|
|
|
7,643
|
|
|
|
6,022
|
|
|
|
7,240
|
|
|
|
6,000
|
|
|
| Outstanding Securities Considered Anti-Dilutive |
Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income (loss) per share available to common stockholders (in thousands):
|
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
Convertible preferred stock (as converted)
|
|
|
—
|
|
|
|
—
|
|
|
|
3,732
|
|
|
|
—
|
|
|
Common stock options and RSUs
|
|
|
1,138
|
|
|
|
554
|
|
|
|
1,391
|
|
|
|
544
|
|
|
Warrants for common stock
|
|
|
19
|
|
|
|
917
|
|
|
|
19
|
|
|
|
914
|
|
|
Total
|
|
|
1,157
|
|
|
|
1,471
|
|
|
|
5,142
|
|
|
|
1,458
|
|
|